German biotech firm Topas raises €22m in series-B round

The financing round also saw participation from all of Topas's existing investors, which include Epidarex Capital, Gimv, EMBL Ventures, Evotec and Boehringer Ingelheim Venture Fund. 

The company, which has so far raised €40m in equity funding, will use the latest proceeds to advance its proprietary pipeline based on its Topas Particle Conjugates technology platform.

This will include progressing TPM203, which is currently in clinical development, and bringing TPM501 – the company's candidate for the treatment of celiac disease – into the clinic.

Previous funding
In March 2016, UK-based VC Epidarex led a €14m series-A round for Topas, which included a €4m equity ticket from listed buyout firm Gimv. In 2017, Topas extended its series-A round to €18m when Boehringer Ingelheim Venture Fund invested €4m in the company.

Company
Founded in 2016 as a carve-out from German pharmaceuticals business Evotec, Topas Therapeutics is a developer of a nanoparticle-based platform to treat autoimmune diseases, allergies and drug-induced immune reaction. It is headquartered in Hamburg and employs 11-50 staff, according to its LinkedIn page.

People
Topas Therapeutics – Klaus Martin (CEO)
Vesalius Biocapital – Marc Lohrmann (managing partner).
BioMedPartners – Michael Wacker (partner).

• Tweet  
• Facebook  
• LinkedIn  
• Google plus  
• Send to  

• Topics
• Early-stage
• Healthcare
• DACH
• Germany
• Venture
• DACH